Lunsumio Approved for Relapsed or Refractory Follicular Lymphoma
Lunsumio is a first-in-class CD20xCD3 T-cell engaging bispecific antibody that targets CD20 on the surface of B cells and CD3 on the surface of T cells.
Diagnosis & Disease Information
Tecartus Approved for Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
The approval was based on data from the phase 1/2 ZUMA-3 trial which evaluated Tecartus in 71 adults with relapsed or refractory B-cell precursor ALL.
Consolidative Stem Cell Transplant May Improve Outcomes Among Patients With Peripheral T-Cell Lymphoma
Researchers sought to determine whether patients with PTCL who have a complete response after A+CHP would benefit from SCT.
Physical Exercise During Chemotherapy Feasible, Associated With Favorable Outcomes
Researchers sought to determine whether initiating exercise during chemotherapy was superior to initiation after chemotherapy.
Breast Implant-Associated Cancers: What Providers and Patients Need to Know
Patients with breast implants are at risk of developing squamous cell carcinoma and various types of lymphoma in the capsules around the implants.
Blood Test Shows Promise for Detecting Cancers Without Approved Screening Tests
A novel blood test can detect cancers that currently have no standard screening procedures, a study suggests.
Improving Cancer Care for Transgender Patients
Transgender patients with cancer may be less likely to receive adequate care and have worse outcomes than their cisgender counterparts.
Breyanzi Approved as Second-Line Treatment for Large B-Cell Lymphoma
The expanded approval was based on data from the phase 3 TRANSFORM and phase 2 PILOT studies.
Fever of Unknown Origin Features Later Diagnosed as Lymphoma
Researchers sought to define clinical and prognostic features associated with fever of unknown origin in patients later diagnosed with lymphoma.
Kymriah Gets Accelerated Approval for Relapsed/Refractory Follicular Lymphoma
The accelerated approval for Kymriah was based on data from the phase 2 ELARA trial.
- Loading...
Loading...
Loading... 
Loading...